A Delaware federal judge on Wednesday wiped out a $235 million verdict against Teva Pharmaceuticals for supposedly infringing a GlaxoSmithKline plc patent for the hypertension drug Coreg.

U.S. District Chief Judge Leonard P. Stark of the District of Delaware ruled in a post-trial opinion that the evidence in the case did not support a jury’s finding in June that Teva’s ”skinny label” for a generic version of the drug had caused doctors to infringe GSK’s patent.